newsfilter
← Latest News
Business Wire·

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment – – Real-World Evidence Provides Insight into Early U.S. Adoption of